Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act

Robin Feldman

doi:10.1371/journal.pmed.1004381

Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act

PLoS Med. 2024 Apr 25;21(4):e1004381. doi: 10.1371/journal.pmed.1004381. eCollection 2024 Apr.

Author

Robin Feldman¹

Affiliation

¹ University of California Law, San Francisco, California, United States of America.

Abstract

In this Policy Forum piece, Robin Feldman discusses how current legislation contributes to informational deficits around drug patents for biologic drugs in the United States.

Copyright: © 2024 Robin Feldman. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biological Products
Biosimilar Pharmaceuticals*
Humans
Intellectual Property*
Legislation, Drug
Patents as Topic / legislation & jurisprudence
United States
United States Food and Drug Administration / legislation & jurisprudence

Substances

Biosimilar Pharmaceuticals
Biological Products

Grants and funding

The author received no specific funding for this work.